Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/34—Gestagens

Definitions

• the pulmonary administration has other particularities.
• the constitution of the pulmonary alveoli is very specific and allows the active ingredient to pass directly into the blood, hence the interest of the method.
• the pulmonary administration is therefore distinguished from the administrations at the level of the mucous membranes as previously mentioned, as well as the cutaneous or oral administrations.
• the bioavailability of the active ingredients, when the drugs are administered by these routes, is often limited.
• a second approach consisted in the administration, directly in a liquid form, of very poorly soluble compounds already solubilized, organized in emulsified systems preferentially of the oil in water type.
• These systems were originally developed to provide parenteral nutrition (Intralipid ® systems of the type, Japanese Patent No. 55 476) have been extended to the oral route, for the solubilization of hydrophobic insoluble active compounds.
• Such systems mainly concern active lipop iles molecules and have the drawback of being difficult to adapt to oral unit presentations.
• Recently, more sophisticated systems, constituting a "pre-concentrate" of surfactants and co-solvent have been developed.
• the invention relates to the use in a pharmaceutical composition
• a pharmaceutical composition comprising at least one active principle, of at least one lipoamino acid constituted by the association between a fatty acid and an amino acid, the fatty acid comprising from 4 to 40 carbon atoms and the amino acid may be a natural, synthetic or modified amino acid, which may be in native or salified form; the lipoamino acid being either a promoter of intestinal absorption or a promoter of pulmonary absorption, depending on whether the composition is respectively in a galenic form suitable for oral administration or in a galenic form suitable for administration in the lungs.
• aspartic acid glutamic acid, alanine, arginine, carnitine, choline, cysteine, glycine, histidine , Isoleucine, leucine, lysine, methionine, phenylalanine, proline, ornithine, taurine, threonine, tryptophan, tyrosine, serine or valine.
• Examples 1 to 8 describe formulations of dispersed systems comprising one or more lipoamino acids (in bold) and their preparation process. These dispersed systems are more particularly of the water in oil type (Examples 2 to 7), that is to say with a hydrophilic dispersed phase and a lipophilic dispersing phase. While Example 8 describes an oil-in-water dispersed system, that is to say with a lipophilic dispersed phase and a hydrophilic dispersing phase.
• a hydrophilic phase consisting of at least one hydrophilic compound and of the active ingredient (s), heated between 40 and 80 ° C.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Endocrinology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Virology (AREA)
• Diabetes (AREA)
• Transplantation (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26212940

Family Applications (1)

Country Status (5)

Families Citing this family (24)

Family Cites Families (9)

• 2001
  • 2001-05-30 FR FR0107051A patent/FR2828102B1/fr not_active Expired - Fee Related
• 2002
  • 2002-03-28 EP EP02724387A patent/EP1372730A1/de not_active Withdrawn
  • 2002-03-28 WO PCT/FR2002/001101 patent/WO2002076506A1/fr not_active Application Discontinuation
  • 2002-03-28 CA CA002441824A patent/CA2441824A1/fr not_active Abandoned
  • 2002-03-28 US US10/473,312 patent/US20040147578A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events